Biology subjects

Barron, M. P.

Publications and source records attributed to Barron, M. P..

4 recordsLinked to original sources

bioRxiv2026

EXOSC3 G191 Variants Trigger System-Wide Recalibration of RNA Processing Machinery

Pathogenic variants in EXOSC3, a noncatalytic subunit of the RNA exosome, cause pontocerebellar hypoplasia type 1B (PCH1B), yet substantial variability in disease severity is observed among individuals carrying different EXOSC3 alleles. The molecular mechanisms of RNA exosome dysfunction in individuals carrying EXOSC3 p.G191 variants remains unresolved. To address this, we generated CRISPR/Cas9-engineered human cell models harboring EXOSC3 p.G191 variants and performed integrated transcriptomic, proteomic, and computational structural analyses. EXOSC3 p.G191 variants produced extensive, allele- and dosage-dependent alterations in gene expression and splicing, with heterozygous variants causing broad but attenuated disruption relative to homozygous EXOSC3 G191D/G191D cells. All EXOSC3 G191 variants promoted increased skipping of exon 3 in EXOSC3 transcripts, generating a short isoform predicted to encode an unstable proteoform. Molecular dynamics and {lambda}-dynamics simulations predicted substantial thermodynamic destabilization of all EXOSC3 G191 variant proteoforms, consistent with reduced protein abundance and thermal stability measured by global proteomics and PISA. At the protein complex level, EXOSC3 p.G191 variants were associated with coordinated decreases in all RNA exosome core subunits and the exonuclease EXOSC10, consistent with destabilization of RNA exosome assembly and orphan protein decay. In contrast, the catalytic exonuclease DIS3 and multiple independent RNA processing pathways were upregulated, indicating compensatory recalibration of RNA metabolism. Together, these findings link variant-induced alternative splicing, RNA exosome complex destabilization, and adaptive network responses to phenotypic variability in EXOSC3 p.G191-associated disease.

systems biology↗

bioRxiv2025

Quantifying the Structural and Energetic Consequences of EXOSC3 S1 Domain Variants from a Comparative Assessment of {lambda}-Dynamics with Two Charge-Changing Perturbation Strategies

Charge-changing perturbations are notoriously dificult to investigate with alchemical free energy calculations. The routine use of periodic boundary conditions and electrostatic approximations, such as particle-mesh Ewald (PME), may produce finite-size efect errors that become non-negligible as a perturbation changes a simulation cells net charge away from zero. Two prevalent strategies exist to correct for these errors: the analytic correction (AC) and co-alchemical ion (CI) methods. Both correction schemes have been found to produce comparable relative free energy results for small molecule perturbations, but these methods have not been compared using {lambda}-dynamics ({lambda}D) free energy calculations or for protein side chain mutations. Recently, we investigated relative folding and binding free energies ({Delta}{Delta}Gs) of a series of EXOSC3 variants involved in a rare neurodegenerative disorder, including D132A, G135R, and G191D charge-change perturbations, with a simplified AC scheme in {lambda}D. In this study, these perturbations are reevaluated with the CI scheme for comparison with AC to identify the best correction strategy for {lambda}D. The collected AC- and CI-corrected {Delta}{Delta}Gs show excellent agreement with a mean unsigned error of 0.4 kcal/mol. However, reduced sampling proficiency and increased dificulties of evaluating multisite perturbations with the CI method suggest that a simplified AC approach may be more generalizable for future {lambda}D calculations. Previously, the use of the CI approach with {lambda}D has been limited due to a lack of infrastructure available to users to simplify its more involved setup procedure. This study introduces an automated workflow for implementation of the CI approach with {lambda}D, laying the foundation for future comparisons between charge-change correction schemes. These studies facilitated analysis of the {lambda}D trajectories to identify structural changes within EXOSC3 and the RNA exosome complex that clearly rationalize the calculated {Delta}{Delta}Gs for the D132A, G135R, G191C, and G191D EXOSC3 variants, providing insight into potential disease-causing mechanisms of EXOSC3 modifications.

biophysics↗

bioRxiv2025

EXOSC3 S1-domain variants implicated in PCH1b alter RNA exosome cap subunit abundance and thermal stability disrupting rRNA processing and targeting of AU-rich mRNA

Missense variants in EXOSC3, an RNA exosome subunit, have been identified in patients with PCH1b. We investigated three missense variants in the S1 domain of EXOSC3, including one variant of uncertain significance (VUS) and two pathogenic variants (hence S1 variants). EXOSC3 S1 variant cell lines were generated using CRISPR-Cas9 resulting in widespread proteome changes including decreases in some RNA exosome subunits paired with increases in the catalytic subunit DIS3. Thermal stability, analyzed by PISA, revealed extensive destabilization of RNA exosome cap subunits and the cap-associated exonuclease EXOSC10. Functionally, S1 variants altered rRNA processing with corresponding protein compensation observed in rRNA processing proteins outside the RNA exosome. Exogenous overexpression of EXOSC3 rescues many molecular defects caused by S1 variants suggesting that protein destabilization and turnover strongly contribute to molecular defects. Overall, our findings define the mechanisms through which cells respond to EXOSC3 S1 variant disruption of RNA processing homeostasis.

systems biology↗

bioRxiv2024

A {lambda}-dynamics investigation of insulin Wakayama and other A3 variant binding affinities to the insulin receptor

Insulin Wakayama is a clinical insulin variant where a conserved valine at the third residue on insulins A chain (ValA3) is replaced with a leucine (LeuA3), impairing insulin receptor (IR) binding by 140-500 fold. This severe impact on binding from such a subtle modification has posed an intriguing problem for decades. Although experimental investigations of natural and unnatural A3 mutations have highlighted the sensitivity of insulin-IR binding to minor changes at this site, an atomistic explanation of these binding trends has remained elusive. We investigate this problem computationally using {lambda}-dynamics free energy calculations to model structural changes in response to perturbations of the ValA3 side chain and to calculate associated relative changes in binding free energy ({Delta}{Delta}Gbind). The Wakayama LeuA3 mutation and seven other A3 substitutions were studied in this work. The calculated {Delta}{Delta}Gbind results showed high agreement compared to experimental binding potencies with a Pearson correlation of 0.88 and a mean unsigned error of 0.68 kcal/mol. Extensive structural analyses of {lambda}-dynamics trajectories revealed that critical interactions were disrupted between insulin and the insulin receptor as a result of the A3 mutations. This investigation also quantifies the effect that adding an A3 C{delta} atom or losing an A3 C{gamma} atom has on insulins binding affinity to the IR. Thus, {lambda}-dynamics was able to successfully model the effects of subtle modifications to insulins A3 side chain on its protein-protein interactions with the IR and shed new light on a decades-old mystery: the exquisite sensitivity of hormone-receptor binding to a subtle modification of an invariant insulin residue. SIGNIFICANCE STATEMENTThis work addresses a decades-old question of how subtle modifications to insulins A3 side chain affects its binding affinity to the insulin receptor. {lambda}-Dynamics computed free energies of binding match experimental activity trends with high accuracy. Atomistic insights into hormone-receptor protein-protein interactions were obtained through a detailed investigation of {lambda}-dynamic trajectories. This work quantifies the effects of adding and removing atoms to insulins conserved A3 residue and identifies clear conformational preferences for insulin A3 residues when bound to the insulin receptor.

biophysics↗